We are live on
!
Find out more
DA
DCF Advisers Portfolio holdings
AUM
$375M
1-Year Est. Return
72.65%
This Fund
S&P 500
This Quarter
Est. Return
+6.85%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$25.9M
(+16%)
Cap. Flow
+$19M
Cap. Flow
% of AUM
10.03%
Top 10 Holdings %
Top 10 Hldgs %
53.85%
Holding
93
New
27
Increased
23
Reduced
15
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$2.5M |
| 2 |
Turning Point Brands
TPB
|
+$1.88M |
| 3 |
Amgen
AMGN
|
+$1.6M |
| 4 |
Johnson & Johnson
JNJ
|
+$987K |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$588K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$3.59M |
| 2 |
Biogen
BIIB
|
+$1.36M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.08M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$713K |
| 5 |
Newmont
NEM
|
+$368K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.09% |
| 2 | Technology | 14.46% |
| 3 | Communication Services | 6.26% |
| 4 | Consumer Discretionary | 3.14% |
| 5 | Energy | 2.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Air T
AIRT
$75.5M
| $229K | 0.12% |
9,135
-1,663
| -15% | -$42.6K |
|
77
Ovid Therapeutics
OVID
$414M
| $212K | 0.11% |
64,764
-3,500
| -5% | -$11.9K |
|
|
PARA
78
DELISTED
Paramount Global Class B
PARA
| $199K | 0.11% |
+12,500
| New | +$226K |
|
|
IMGN
79
DELISTED
Immunogen Inc
IMGN
| $195K | 0.1% |
+10,350
| New | +$122K |
|
80
United States Natural Gas Fund
UNG
$456M
| $111K | 0.06% |
3,750
| – | – |
|
81
CALL
Wolfspeed
WOLF
$1.23B
| $111K | 0.06% |
+2,000
| New | +$102K |
|
82
Equillium
EQ
$139M
| $83.7K | 0.04% |
111,623
-45,400
| -29% | -$30K |
|
|
TBHC
83
DELISTED
The Brand House Collective
TBHC
| $76K | 0.04% |
27,235
| – | – |
|
|
AMRN
84
Amarin Corp
AMRN
$298M
| $29.8K | 0.02% |
+1,250
| New | +$32.1K |
|
85
CALL
Lifecore Biomedical
LFCR
$166M
| $29K | 0.02% |
+3,000
| New | +$18.3K |
|
86
PUT
Burford Capital
BUR
$903M
| $24.4K | 0.01% |
+2,000
| New | +$25.9K |
|
87
Lineage Cell Therapeutics
LCTX
$269M
| $21.1K | 0.01% |
+15,000
| New | +$20.7K |
|
|
88
Biogen
BIIB
$30B
| – | – |
-4,900
| Closed | -$1.36M |
|
|
89
CALL
Burford Capital
BUR
$903M
| – | – |
-34,500
| Closed | -$382K |
|
|
90
Newmont
NEM
$98.7B
| – | – |
-7,500
| Closed | -$368K |
|
91
Starbucks
SBUX
$120B
| – | – |
-2,000
| Closed | -$208K |
|
Similar funds
JIC
CIM
AIM
MWM
RCP
HPM
CAG
LWMNY
DCF Advisers's Q2 2023 Portfolio in Review
As of Q2 2023, DCF Advisers held 93 positions worth $189M, up 16% from $163M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
DCF Advisers deployed $19M of net new capital in Q2 2023, opening 27 new positions and adding to 23 existing holdings. Its largest new stake was Zimmer Biomet: 18,397 shares worth $2.68M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 40% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was AbbVie, an estimated $3.59M trimmed.
- DCF Advisers's largest Q2 2023 buy was Zimmer Biomet: 18,397 shares worth $2.68M.
- DCF Advisers added most to Amgen in Q2 2023, an estimated $1.6M increase.
- DCF Advisers's biggest Q2 2023 reduction was AbbVie, cutting an estimated $3.59M.
- DCF Advisers fully exited Biogen in Q2 2023, selling an estimated $1.36M.
- DCF Advisers's ten largest holdings make up 54% of its $189M portfolio in Q2 2023.
- DCF Advisers opened 27 new positions and closed 5 in Q2 2023.
- DCF Advisers's portfolio value rose 16% quarter-over-quarter to $189M.
Based on DCF Advisers's 13F filing for Q2 2023, filed 9 Aug 2023.